Janus Pharmaceuticals

Sound Pharmaceuticals is a biopharmaceutical company that develops therapeutics for the prevention and treatment of hearing loss. The company's offerings include oral and locally delivered treatments for sensorineural hearing loss and tinnitus, as well as solutions for acute and chronic ototoxicity. Sound Pharmaceuticals targets inner ear disorders. It was founded in 2002 and is based in Seattle, Washington.

Clal Biotechnology Industries is a public investment firm targeting pre-clinical, seed, start-up, early venture, emerging growth and growth capital stages of financing that was founded in 1998 and based in Tel Aviv, Israel. Clal primarily invests in biopharmaceutical and biotech companies. Generally, Clal Biotechnogy Industries looks to invest up to $10 million per company and prefers to be lead investor and take a board seat. It also seeks to take a majority share in its portfolio companies.

Bikam Pharmaceuticals is a biopharmaceutical company. It focuses on the discovery and development of small-molecule therapeutics for the treatment of ophthalmic diseases and disorders, including retinitis pigmentosa. It was founded in 2007 and is based in Cambridge, Massachusetts.

VidaGene,Inc., is a biopharmaceutical company that aims to develop pharmaceuticals based on modulation of the vitamin D receptor (VDR). VidaGene seeks to develop entirely new VDR modulators for large pharmaceutical markets such as cancer-related thrombosis, osteoporosis and psoriasis.

Oligomerix is a biotechnology company focused on developing therapeutics for neurodegenerative diseases associated with tau protein abnormalities. The company provides small molecule inhibitors that target tau self-association to address tau-related diseases. Oligomerix serves the healthcare sector with treatments for conditions like Alzheimer's disease and rare tauopathies. It was founded in 2006 and is based in West Harrison, New York.

BrainCells is a biopharmaceutical company focused on the development of small molecule therapeutics for diseases of the central nervous system (CNS). The company's technology platform is based on research in the field of neurogenesis and recent discoveries linking neurogenesis to CNS disease states. BCI is using its neurogenesis technology platform to identify clinical-stage compounds, targets and compounds optimal for CNS indications. BCI is building a pipeline of clinical-stage programs to address unmet medical needs in the treatment of mood disorders, psychoses, cognition, brain repair syndromes and other CNS disorders.